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Abstract. The behavioural aspects of pre-exposure prophylaxis (PrEP) are challenging, particularly the issue of condom
migration. Three vital questions are: (1) at the population-level, will condom migration lead to increases in non-viral
sexually transmissible infections?; (2) how can clinic-based counselling best promote the dual use of condoms and PrEP?;
and (3) in future PrEP trials, what are the ‘best practices’ that should be used to avoid type 1 and type 2 errors that arise
without accounting for condom use behaviours? This communication piece addresses each question and suggests the risk
of a ‘PrEP only’ focus to widening health disparities.
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Introduction
Globally, the stage is set for pre-exposure prophylaxis (PrEP)
to become a mainstay of HIV prevention.1–3 The behavioural
aspects of PrEP, however, may prove challenging.4 Uptake
and adherence issues have emerged as a result of PrEP.5–12
A third behavioural issue has received much less attention: the
occurrence of condom migration. This phenomenon occurs
when perceived protection from one prevention method
precludes, or reduces, the use of a second method.13–16 In the
field of sexual health, this concept was initially described relative
to the inverse association between hormonal contraceptive use
and condoms17–21 (thus prompting the practice of promoting
dual use).22
Rather than reviewing current evidence pertaining to condom
migration, this communication piece suggests that the question
of whether individual-level condom use decreases, stays the
same, or increases during periods of PrEP use, is not a useful
one because it provides little practical information relative
to prevention. Instead, there are three questions that are
highly pertinent to public health: (1) at the population-level,
will condom migration lead to substantial increases in non-viral
sexually transmissible infections (STIs)?; (2) at the individual-
level, how can PrEP-associated counselling sessions best
promote the dual use of condoms and PrEP?; and (3) in
future clinical trials of PrEP, what are the ‘best practices’ that
should be used to avoid type 1 and type 2 errors that may arise in
the absence of precisely accounting for condom use behaviours?
Rather than conflating heterosexual populations with
populations of MSM, this communication piece will primarily
focus on PrEP-associated condom migration issues that pertain
to the national emergencies among MSM. The crisis among
MSM is severe and the corresponding health disparity for MSM
is becoming larger, especially for minority MSM.23,24
Population-level condom migration
Auerbach and Hoppe suggested that the issue of condom
migration is not important because PrEP efficacy is strong
enough to offer protection without condom use and robust to
the synergistic effect of STIs on the acquisition and transmission
of HIV.25 This point is quite valid, but it is made in the paradigm
of ending AIDS.26 Moving away from an ‘ending AIDS only’
paradigm to a larger paradigm of sexual health, it is noteworthy
in the United States that 2014 surveillance data showed
substantial increases in STI cases occurring, for the first time
in more than one decade.27 Whether population-level increases
in STIs are occurring as a result of PrEP use, is a very different
question than one addressed in other studies, such as that
reported by Volk et al. who noted a substantial (28.4%)
12-month incidence of non-viral STIs among 657 PrEP
initiators.28 Whether non-HIV viral STIs (e.g. HPV, herpes)
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may similarly increase is questionable given the relatively low
efficacy of condoms against these infections; nonetheless, small
increases are possible. If PrEP-associated condom migration is
a contributing factor to population-level increases in STIs, it
would occur through a network-based spread of infections.
Thus, simply assessing STI incidence in only those using
PrEP would be inadequate.
Given the intent of PrEP for persons other than those having a
primary seropositive sex partner, it is quite plausible that many
people taking PrEP occupy fairly central positions in their sexual
networks. Thus, even small amounts of PrEP-associated condom
migration, or a perceived freedom to increase the number of sex
partners, may substantially amplify STI transmission rates. The
only way to rule out the possibility of PrEP being a cause of
greater STI incidence rates is to find an absence of correlation
between PrEP consumption (perhaps assessed through aggregate
data from pharmacies) and STI rates. The absence of at least a
moderate correlation would negate the possibility of a cause-
and-effect relationship. Conversely, the presence of at least a
moderate correlation would only suggest potential causation,
thereby warranting more definitive, and costly, study designs.
Clearly, causes other than PrEP-associated condom
migration may be relevant. For instance, it is likely that
people most at-risk of HIV acquisition (thus prioritised for
PrEP) are also very likely to be involved in sexual networks
where STI prevalence is high, and through the frequent STI
screenings, greater case findings occur that are then mistaken as
upward trends.29 Also, it is possible that health departments have
diverted resources to PrEP implementation that were previously
allocated to STI-prevention and -control activities, such as
contact tracing.
Dual use of PrEP and condoms
Emerging evidence suggests that adherence to PrEP may be
low. Failed PrEP trials were attributed to poor adherence30,31
and successful PrEP trials have restricted the analyses to
adherent persons. This low level of adherence in efficacy trials
bodes poorly for adherence in practice, given the absence of
tightly controlled conditions found in clinical trials.32 Poor
adherence is one reason why researchers have tested PrEP use
as ‘sexualactivitydependent’ (a strategywithpromisingresults)33
and why other researchers have advocated that PrEP only be
provided in the context of behavioural intervention programs.34
Adherence challenges are compounded by the fact that, unlike
antiretrovirals to treat HIV people taking PrEP are disease-
free.35
Prior to PrEP, the prevention method of choice was the
consistent and correct use of latex condoms. All too often,
the ‘correct’ portion of the phrase ‘consistent and correct
condom use’ is ignored by researchers.13,36,37 A case in point
applies to a recent study of condom effectiveness against non-
viral STIs among heterosexuals.38 This multi-site study found a
non-significant overall association between the consistent use of
condoms and the acquisition of non-viral STIs, in both males
and females. However, much like PrEP trials only analysing
adherent study participants, the association became significant
(and strong; adjusted odds ratio of 0.41) after refining the
classification to consistent and correct use. Similar bias
towards the null hypothesis applies to condom effectiveness
studies for HIV conducted among heterosexuals. Thus, condoms
may be far more efficacious than the current estimates suggest.
Consequently, evidence-based interventions applied to promote
the correct, as well as the consistent use of, condoms may be
as efficacious as PrEP.39–41 It is noteworthy that the most
recently published study on condom effectiveness against
HIV acquisition among MSM provided a 70% effectiveness
rate for persons using condoms consistently.42 The study,
however, did not correct for lack of correct use among those
using condoms consistently, thereby creating bias towards the
null.38,43,44 Assuming 70% as a conservative estimate of
effectiveness, correct condom use is nonetheless as effective
(or better) as estimates of PrEP efficacy obtained in the original
study of MSM (point estimate = 44%, 95% CI = 15–63%).3
That both PrEP and condom use can be equally effective
against HIV acquisition is an important counselling point for
clinicians. The PrEPare study, for instance, found that 40% of
MSM reported that avoiding condomless sex was their HIV
prevention strategy and that 47.5% reported having condomless
sex but using PrEP.45 Clearly, not all MSM desire to be on PrEP
and thus presenting men with multiple prevention options is an
ethical and beneficial practice. BecauseMSMmay use PrEP on a
situation-specific basis (e.g. weekends only) and the expense of
PrEP makes its use impractical during times when MSM do not
have anal sex, the option of condom use (either fully or as a
supplement to PrEP) must be delivered as a practical alternative
or companion practice to PrEP, and clinics should consider using
evidence-based counselling programs that promote the correct
and consistent use of condoms in a sex-positive context.40 This
same ethic of dual use should also be applied to future PrEP
delivery strategies that may be sexual-activity dependent.33
Best measurement practices for condom use among
PrEP users
Failed trials of PrEP, such as that reported by Van Damme
et al.,30 may have been confounded by condommigration. If, for
example, women (and/or their HIV-positive male sex partners)
believing they were taking PrEP largely abandoned condom use
and did not fully adhere to PrEP, this would explain the greater
incidence of new infection in the intervention group. In future
trials of PrEP, it will be critical to conduct rigorous assessments
of condom use. Ideally, assessments should be made at the
event-level, meaning that they occur soon after (e.g. 24 h) sexual
events.44,46–48 The primary confounding issue with aggregate
measures of condom use is that it will not be possible to know
whether PrEP use and condom use occurred simultaneously
or separately. For example, a person taking PrEP only on
weekends – perhaps when having sex with side partners –
and also reporting condomless anal receptive sex twice each
week may be fully protected or at-risk of HIV acquisition. If
Tenofovir disoproxil fumarate levels are sufficiently high for
the weekend sexual events and the two events of condomless
sex occurred at this time, then protection is conferred, as
planned. However, if the condomless events occurred during
the week (e.g. Wednesday/Thursday) when Tenofovir levels
were low, then risk of HIV acquisition (from perhaps a
serodiscordant main partner) may be high. Because this type
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of ‘weekend’ PrEP use was tested in the Ipergay study and found
to be effective,33 it may become a common method of delivery.
Thus, for now and in the future, simply assessing the number
of days when PrEP was taken and the number of times when
condomless anal sex occurred is not sufficient to avert the risk of
type 1 errors (condoms were used when PrEP was used, thus
inflating the efficacy of PrEP) or type 2 errors (condoms were
used, rather than PrEP, with partners who were seropositive, thus
conferring protection that should not be attributed to PrEP).
Ultimately, the assessment of condom use behaviours in the
context of PrEP-related studies is complex and warrants
much more attention to detail than it has received.3,30,48–50
Table 1 displays a proposed assessment framework that
applies to MSM.
Conclusion
Re-conceptualising PrEP as a complementary tool in the AIDS
pandemic rather than a singular one is imperative. In addition to
the reasons described, this is imperative because prevention
efforts overly focused on PrEP may inadvertently widen the
already existing racial, ethnic and economic disparities in HIV
incidence. This point is clearly illustrated by a recent analysis of
MSM dropping out of care for PrEP. This USA-based study
estimated large cascade effects cumulating in only 12.3% of
Black MSM ultimately benefitting from PrEP compared to
17.8% among White MSM.4 Similar findings have been
reported in other studies.51,52
Until PrEP becomes widely accepted and used correctly by
substantial portions of at-risk populations, the prevention of HIV
acquisition will be reliant on the consistent and correct use of
male latex condoms. Evidence supports the idea that MSM may
often prefer condom use as compared to PrEP,8 and other
evidence suggests that a fair portion (approximately one-
third) of Black MSM may actually enjoy sex more when it is
condom-protected.53
To avert expanding the HIV prevention disparities seen
globally,54,55 the task of the practitioners, policymakers and
Table 1. Proposed condom assessment methodology in studies of pre-exposure prophylaxis use
Question
In the past 90 days, have you had anal sex with a male, as a Top?
If yes, please complete the following grid-
In the past 90 days, how many times did: With HIV-infected
partners
With partners not known
to be HIV-infectedSex occur (with you as the top)?
Of these times (row above) how many Involved condom use from start
to finish?
Of the times condoms were used (row above) how many times did condoms
break, slip off, or slip off during withdrawal?
Of the times condoms were used (2 rows above) how many times were
condoms used that had been used previously for sex?
In the past 90 days, have you had anal sex as a Bottom?
If yes, please complete the following grid-
In the past 90 days, how many times did With HIV-infected
partners
With partners not known
to be HIV-infectedSex occur (with you as the bottom)?
Of these times (row above) how many Involved condom use from start
to finish?
Of the times condoms were used (row above) how many times did condoms
break, slip off, or slip off during withdrawal?
Of the times condoms were used (2 rows above) how many times were
condoms used that had been used previously for sex?
In the past 90 days, have you had oral sex with a male?
If yes, please complete the following grid-
In the past 90 days, how many times did: With HIV-infected
partners
With partners not known
to be HIV-infectedOral sex occur with you giving the blow job?
Of these times (row above) how many Involved condom use from start
to finish?
Of the times condoms were used (row above) how many times did condoms
break, slip off, or slip off during withdrawal?
Of the times condoms were used (2 rows above) how many times were
condoms used that had been used previously for sex? Oral sex occur with
you getting (receiving) the blow job?
Of these times (row above) how many Involved condom use from start
to finish?
Of the times condoms were used (row above) how many times did condoms
break, slip off, or slip off during withdrawal?
Of the times condoms were used (2 rows above) how many times were
condoms used that had been used previously for sex?
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behavioural scientists is to move forward with PrEP and
simultaneously move forward with the less invasive and less
resource-intensive methods that may be more acceptable to
persons most at-risk of HIV acquisition.
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